[go: up one dir, main page]

MXPA03007130A - Conjugados de peg de hgf-nk4. - Google Patents

Conjugados de peg de hgf-nk4.

Info

Publication number
MXPA03007130A
MXPA03007130A MXPA03007130A MXPA03007130A MXPA03007130A MX PA03007130 A MXPA03007130 A MX PA03007130A MX PA03007130 A MXPA03007130 A MX PA03007130A MX PA03007130 A MXPA03007130 A MX PA03007130A MX PA03007130 A MXPA03007130 A MX PA03007130A
Authority
MX
Mexico
Prior art keywords
hgt
conjugates
peg
Prior art date
Application number
MXPA03007130A
Other languages
English (en)
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03007130A publication Critical patent/MXPA03007130A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA03007130A 2001-02-23 2002-02-21 Conjugados de peg de hgf-nk4. MXPA03007130A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01104640A EP1234583A1 (en) 2001-02-23 2001-02-23 PEG-conjugates of HGF-NK4
PCT/EP2002/001837 WO2002074344A2 (en) 2001-02-23 2002-02-21 Peg-conjugates of hgt-nk4

Publications (1)

Publication Number Publication Date
MXPA03007130A true MXPA03007130A (es) 2003-11-18

Family

ID=8176596

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03007130A MXPA03007130A (es) 2001-02-23 2002-02-21 Conjugados de peg de hgf-nk4.

Country Status (27)

Country Link
US (2) US20030012775A1 (es)
EP (2) EP1234583A1 (es)
JP (2) JP2004521139A (es)
KR (2) KR20030072629A (es)
CN (1) CN100339393C (es)
AR (1) AR032574A1 (es)
AU (1) AU2002233354B2 (es)
BG (1) BG108125A (es)
BR (1) BR0207510A (es)
CA (1) CA2438308A1 (es)
CZ (1) CZ20032511A3 (es)
EC (1) ECSP034741A (es)
GT (1) GT200200038A (es)
HR (1) HRP20030659A2 (es)
HU (1) HUP0400979A2 (es)
IL (1) IL157426A0 (es)
MA (1) MA26998A1 (es)
MX (1) MXPA03007130A (es)
NO (1) NO20033737L (es)
PA (1) PA8540501A1 (es)
PE (1) PE20020992A1 (es)
PL (1) PL367402A1 (es)
RU (1) RU2293574C2 (es)
SK (1) SK11652003A3 (es)
WO (1) WO2002074344A2 (es)
YU (1) YU65103A (es)
ZA (1) ZA200306080B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
JP2007525425A (ja) * 2003-03-24 2007-09-06 ノボ ノルディスク アクティーゼルスカブ Glp−2誘導体
CA2558742A1 (en) * 2004-03-03 2005-10-13 F. Hoffmann-La Roche Ag Method for the recombinant expression of an n-terminal fragment of hepatocyte growth factor
JP4511589B2 (ja) * 2004-03-03 2010-07-28 エフ.ホフマン−ラ ロシュ アーゲー 肝細胞成長因子のn末端フラグメントを精製するための方法
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
EP2281040B1 (en) * 2008-04-09 2015-11-25 Viromed Co., Ltd. Lyophilized dna formulations for enhanced expression of plasmid dna
CN102399293B (zh) * 2008-06-03 2013-12-04 中国科学院遗传与发育生物学研究所 一种与纤维蛋白特异结合的重组蛋白及其应用
US10532020B2 (en) 2012-08-22 2020-01-14 Revlon Consumer Products Corporation Nail coatings having enhanced adhesion
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン-10
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン10の使用方法
CN113382775A (zh) * 2019-01-28 2021-09-10 东丽株式会社 肝细胞生长因子或其活性片段的聚乙二醇修饰物
WO2020158691A1 (ja) * 2019-01-28 2020-08-06 東レ株式会社 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118012A1 (en) 1992-05-18 1993-11-25 Paul J. Godowski Hepatocyte growth factor variants
US6472178B1 (en) 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
JP2996415B2 (ja) * 1994-03-31 1999-12-27 アムジエン・インコーポレーテツド 巨核球の成長と分化を刺激するモノpeg化mgdfポリペプチド
RU2158603C2 (ru) * 1994-05-31 2000-11-10 Амген Инк. Способы и препараты для стимулирования роста и дифференцировки мегакариоцитов
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
EP0741187A2 (en) * 1995-05-05 1996-11-06 F. Hoffmann-La Roche Ag Recombinant obese (Ob) proteins
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
AU725133B2 (en) 1997-01-15 2000-10-05 Polaris Group Modified tumor necrosis factor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP0922446A1 (en) * 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CN100335503C (zh) * 1998-04-28 2007-09-05 应用研究系统Ars股份公司 多元醇干扰素β偶联物
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JO2291B1 (en) * 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2431964C (en) * 2000-12-20 2013-09-10 F. Hoffmann-La Roche Ag Conjugates of erythropoietin (pep) with polyethylene glycol (peg)

Also Published As

Publication number Publication date
HUP0400979A2 (hu) 2004-08-30
RU2003127395A (ru) 2005-03-20
YU65103A (sh) 2006-03-03
HRP20030659A2 (en) 2004-08-31
JP2004521139A (ja) 2004-07-15
AR032574A1 (es) 2003-11-12
IL157426A0 (en) 2004-03-28
PE20020992A1 (es) 2002-11-01
BR0207510A (pt) 2004-07-27
CN1571679A (zh) 2005-01-26
WO2002074344A3 (en) 2003-12-04
NO20033737L (no) 2003-10-21
KR20030072629A (ko) 2003-09-15
ECSP034741A (es) 2003-10-28
KR20090020713A (ko) 2009-02-26
US7846896B2 (en) 2010-12-07
SK11652003A3 (sk) 2004-05-04
RU2293574C2 (ru) 2007-02-20
MA26998A1 (fr) 2004-12-20
AU2002233354B2 (en) 2006-11-30
CZ20032511A3 (en) 2004-03-17
US20080085857A1 (en) 2008-04-10
BG108125A (bg) 2004-09-30
US20030012775A1 (en) 2003-01-16
EP1234583A1 (en) 2002-08-28
PA8540501A1 (es) 2002-09-30
JP2010174034A (ja) 2010-08-12
NO20033737D0 (no) 2003-08-22
GT200200038A (es) 2002-09-30
EP1389132A2 (en) 2004-02-18
CN100339393C (zh) 2007-09-26
CA2438308A1 (en) 2002-09-26
WO2002074344A2 (en) 2002-09-26
ZA200306080B (en) 2004-11-23
PL367402A1 (en) 2005-02-21

Similar Documents

Publication Publication Date Title
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
DE60229476D1 (en) Biosensor
DE60205702D1 (en) Biosensor
HU0401339D0 (en) Novel 4-anilinoquinoline-3-carboxamides
AU2002357860A8 (en) Enzymes
ZA200208561B (en) Hydraulischer druckverstarker.
MXPA03007130A (es) Conjugados de peg de hgf-nk4.
EP1421371A4 (en) BIOSENSOR
MXPA01009037A (es) I-bet.
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
GB2376928B (en) Personal hoverplane having four tiltmotors
HU0400176V0 (en) Improved gasketseal
EG23036A (en) Novel pyrrolecarboxamides
PL364076A1 (en) Novel pyridylmethylaminopyrimidines
GB0102946D0 (en) Enzyme
GB0121840D0 (en) Modified enzyme
AU2002364178A8 (en) Ownership of part-physical, part-virtual devices
HU0104370D0 (en) Honeyed schnaps of oerseg
IL142466A0 (en) Insect-selective neurotoxin
GB0124575D0 (en) Enzyme
GB0110044D0 (en) Enzyme
CA93850S (en) Biosensor
HU0101309D0 (en) Modified laparoscope - gripper
GB0118494D0 (en) P.c.o.
GB0116210D0 (en) P.c.o

Legal Events

Date Code Title Description
FA Abandonment or withdrawal